LOC55908, also known as angiopoietin-like 8 (ANGPTL8), is a protein that has garnered significant attention within the scientific community due to its role in the complex network of lipid metabolism. This protein operates within the intricate system responsible for the management of triglyceride distribution and fatty acid mobilization within the body. The expression of LOC55908 is an adaptive response to various metabolic demands and states, including energy surplus and deficit, which reflects the body's natural modulation of lipid utilization and storage. Understanding the natural regulators of LOC55908 expression is crucial for comprehending the subtleties of lipid homeostasis. Research indicates that LOC55908 expression can be sensitive to a variety of metabolic shifts, hence the interest in identifying non-protein chemical agents that can induce a decrease in its expression levels, providing insights into the metabolic pathways of lipid processing.
In the quest to delineate the mechanisms underlying the modulation of LOC55908 expression, a range of chemicals has been identified that are thought to influence its expression indirectly through their interaction with broader metabolic pathways. For instance, certain fibrates, such as Fenofibrate, which are known to activate peroxisome proliferator-activated receptors, may contribute to a reduction in LOC55908 expression by promoting lipid catabolism. Similarly, compounds like GW 501516 have been shown to enhance fatty acid oxidation, which could conceivably lead to a decreased necessity for LOC55908's role in energy balance, thereby reducing its expression. Polyunsaturated fatty acids, particularly omega-3 fatty acids like EPA and DHA, might also play a role in diminishing LOC55908 expression by altering cellular lipid composition and inflammatory response cascades. Additionally, small molecules such as Metformin, which modulates glucose metabolism, might have indirect consequences on LOC55908 expression by improving overall metabolic efficiency and lipid profiles. These insights into how various chemicals may influence LOC55908 expression enhance our understanding of lipid metabolism and the body's intrinsic regulatory systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate may downregulate LOC55908 by enhancing the breakdown of triglycerides, thereby reducing the need for LOC55908′s lipid modulating activity. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW 501516 could decrease LOC55908 expression by stimulating fatty acid oxidation pathways, reducing the organism′s reliance on LOC55908 for energy homeostasis. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone may reduce LOC55908 expression through PPARγ activation, which could lead to a decrease in triglyceride synthesis and storage, diminishing LOC55908′s role. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid might downregulate LOC55908 by altering the transcriptional control of genes associated with lipid metabolism and homeostasis. | ||||||
Docosa-4Z,7Z,10Z,13Z,16Z,19Z-hexaenoic Acid (22:6, n-3) | 6217-54-5 | sc-200768 sc-200768A sc-200768B sc-200768C sc-200768D | 100 mg 1 g 10 g 50 g 100 g | $94.00 $210.00 $1779.00 $8021.00 $16657.00 | 11 | |
DHA could inhibit the expression of LOC55908 by shifting the lipid composition of membranes and reducing inflammatory signaling pathways that upregulate LOC55908. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin might decrease LOC55908 expression by attenuating inflammatory mediators that can lead to the upregulation of lipid-related genes like LOC55908. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine may downregulate LOC55908 by improving insulin sensitivity and reducing hepatic glucose production, which could lessen the demand for LOC55908′s function in lipid metabolism. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin could decrease LOC55908 expression by improving insulin sensitivity and altering lipid metabolism, thereby reducing hepatic fat content and the stimulus for LOC55908 expression. | ||||||
Nicotinamide | 98-92-0 | sc-208096 sc-208096A sc-208096B sc-208096C | 100 g 250 g 1 kg 5 kg | $44.00 $66.00 $204.00 $831.00 | 6 | |
Nicotinamide may reduce LOC55908 expression by shifting NAD+ metabolism, leading to changes in the cellular redox state that could downregulate the need for LOC55908. | ||||||
Cholic acid | 81-25-4 | sc-255020 sc-255020A sc-255020B sc-255020C sc-255020D | 25 g 100 g 500 g 1 kg 5 kg | $49.00 $123.00 $578.00 $1018.00 $4570.00 | 11 | |
Cholic acid could decrease LOC55908 expression by interrupting the enterohepatic circulation of bile acids and altering cholesterol homeostasis, potentially reducing the expression of genes like LOC55908 involved in lipid processing. | ||||||